南京医药集团股份有限公司2024年度第一期中期票据2026年付息公告

Group 1 - The company announced the payment details for its 2024 first phase medium-term notes, ensuring the process is smooth and timely [1][4] - The payment funds will be transferred to the designated account of the Central Clearing Corporation before the due date, and any changes in the payment route must be notified in advance [1][4] - The company and its board guarantee the accuracy and completeness of the announcement, taking legal responsibility for its content [1][3] Group 2 - The company also announced the payment details for its 2025 fifth phase short-term financing notes, with similar procedures for fund transfer and notification of changes [4][7] - The payment will be made on the due date, with adjustments for public holidays, and the company will not bear losses due to late notifications from bondholders [4][7] - The company reaffirms its commitment to timely and accurate information disclosure as per regulatory requirements [4][6] Group 3 - The company provided contact information for relevant personnel involved in the issuance and management of the bonds, ensuring transparency and accessibility for bondholders [2][5][8] - The management institutions and custodians are clearly identified, facilitating communication regarding the bonds [2][5][8]